<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-8-20</article-id><article-id pub-id-type="pmid">17428349</article-id><article-id pub-id-type="doi">10.1186/1471-2350-8-20</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association of TGF&#x003b2;1, TNF&#x003b1;, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Prasad</surname><given-names>Pushplata</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pushplata_prasad114@rediffmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Tiwari</surname><given-names>Arun K</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>arun_genet@yahoo.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Kumar</surname><given-names>KM Prasanna</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kmprasanna@vsnl.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Ammini</surname><given-names>AC</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>aca433@yahoo.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Gupta</surname><given-names>Arvind</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>arvindneelum@hotmail.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Gupta</surname><given-names>Rajeev</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>rajeevg@satyam.net.in</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Thelma</surname><given-names>BK</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>humgen@vsnl.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Genetics, University of Delhi South Campus, New Delhi, India</aff><aff id="I2"><label>2</label>Department of Endocrinology and Metabolism, M.S. Ramiah Medical College, Bangalore, India</aff><aff id="I3"><label>3</label>Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India</aff><aff id="I4"><label>4</label>Jaipur Diabetes and Research Centre, Jaipur, India</aff><aff id="I5"><label>5</label>Monilek Hospital and Research Centre, Jaipur, India</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>12</day><month>4</month><year>2007</year></pub-date><volume>8</volume><fpage>20</fpage><lpage>20</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/20"/><history><date date-type="received"><day>17</day><month>6</month><year>2006</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Prasad et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Prasad et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Prasad Pushplata pushplata_prasad114@rediffmail.com </dc:author><dc:title> Association of TGF&#x003b2;1, TNF&#x003b1;, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 8(1): 20-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2007)8:1&#x0003c;20&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Cytokines play an important role in the development of diabetic chronic renal insufficiency (CRI). Transforming growth factor &#x003b2;1 (TGF &#x003b2;1) induces renal hypertrophy and fibrosis, and cytokines like tumor necrosis factor-alpha (TNF&#x003b1;), chemoattractant protein-1 (MCP-1), and regulated upon activation and normal T cell expressed and secreted (RANTES) mediate macrophage infiltration into kidney. Over expression of these chemokines leads to glomerulosclerosis and interstitial fibrosis. The effect of MCP-1 and RANTES on kidney is conferred by their receptors i.e., chemokine receptor (CCR)-2 and CCR-5 respectively. We tested association of nine single nucleotide polymorphisms (SNPs) from TGF&#x003b2;1, TNF&#x003b1;, CCR2 and CCR5 genes among individuals with type-2 diabetes with and without renal insufficiency.</p></sec><sec sec-type="methods"><title>Methods</title><p>Type-2 diabetes subjects with chronic renal insufficiency (serum creatinine &#x02265; 3.0 mg/dl) constituted the cases, and matched individuals with diabetes of duration &#x02265; 10 years and normoalbuminuria were evaluated as controls from four centres in India. Allelic and genotypic contributions of nine SNPs from TGF&#x003b2;1, TNF&#x003b1;, CCR2 and CCR5 genes to diabetic CRI were tested by computing odds ratio (OR) and 95% confidence intervals (CI). Sub-analysis of CRI cases diabetic retinopathy status as dependent variable and SNP genotypes as independent variable in a univariate logistic regression was also performed.</p></sec><sec><title>Results</title><p>SNPs Tyr81His and Thr263Ile in TGF &#x003b2;1 gene were monomorphic, and Arg25Pro in TGF &#x003b2;1 gene and &#x00394;32 polymorphism in CCR5 gene were minor variants (minor allele frequency &#x0003c;0.05) and therefore were not considered for case-control analysis. A significant allelic association of 59029G&#x0003e;A SNP of CCR5 gene has been observed and the allele 59029A seems to confer predisposition to development of diabetic CRI (OR 1.39; CI 1.04&#x02013;1.84). In CRI subjects a compound group of genotypes "GA and AA" of SNP G&#x0003e;A -800 was found to confer predisposition for proliferative retinopathy (OR 3.03; CI 1.08&#x02013;8.50, p = 0.035).</p></sec><sec><title>Conclusion</title><p>Of the various cytokine gene polymorphisms tested, allele 59029A of CCR5 gene is significantly associated with diabetic renal insufficiency among Asian Indians. Result obtained for 59029G&#x0003e;A SNP of CCR5 gene is in conformity with reports from a Japanese population but due to sub-optimal power of the sample, replication in larger sample set is warranted.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Lifestyle and overeating with consequent obesity are major triggering factors for type-2 diabetes epidemic but important underlying pathogenic elements appear to be genetic factors. Positive family history confers a 2.4 fold increased risk and 15&#x02013;25% of first degree relatives of patients with type-2 diabetes develop impaired glucose tolerance. The lifetime risk for type-2 diabetes is 38% if one parent has diabetes and 60% if both the parents are affected [<xref ref-type="bibr" rid="B1">1</xref>]. Multiple susceptibility genes have been reported in pathogenesis of type-2 diabetes as well as diabetic complications such as nephropathy. Clinical diabetic nephropathy results from glomerular, tubular, interstitial and vascular lesions. Genesis of diabetic kidney disease involves both hemodynamic and metabolic pathways and a subset of diabetic patients who develop nephropathy may have a genetic susceptibility to develop renal injury in response to abnormal physiological milieu that is associated with diabetes. There is interplay of metabolic, biochemical and hemodynamic abnormalities that contribute to development of diabetic renal disease and it has been proposed that renin-angiotensin-aldosterone system (RAAS), nitric oxide, and transforming growth factor (TGF)-&#x003b2;1 pathways are important [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>As a part of an extensive analysis of genetic susceptibility to diabetic renal disease, we had earlier reported the role of RAAS gene polymorphisms in diabetic CRI. A highly significant association of Met235Thr, and a weaker association of T&#x0003e;C (-344) and G&#x0003e;A (-1903) SNPs with CRI, independent of hypertension, was observed there in [<xref ref-type="bibr" rid="B3">3</xref>]. It suggested that the effect of RAAS may not be mediated through modulation of hypertension as a crucial mechanism for development of CRI but it may operate by stimulation of chemokines like transforming growth factor &#x003b2;1 (TGF&#x003b2;1), tumor necrosis factor &#x003b1; (TNF&#x003b1;) and interleukin 1 (IL1). Hyperglycemia and systemic hypertension leads to glomerular hypertension as a result of ineffective preglomerular resistances, which are possibly genetically determined [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Glomerular hypertension in early stages of nephropathy leads to changes in endothelial and mesangial cells. The resultant increased expression of glucose transporter-1 (GLUT-1) leads to increased production of TGF&#x003b2;1 and formation of advanced glycation end-products (AGE) and its receptor [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. This promotes deposition of collagens I, III and fibronectin. Activation of mitochondrial protein kinase-C (PKC) also leads to production of TGF&#x003b2;1, superoxide and peroxynitrite and decreases activity of nitric oxide. This decreased activity increases angiotensin II and angiotensinogen II type-1 receptor which loop back upstream in the cascade increasing glomerular hypertension and expression of TGF&#x003b2;1 and GLUT-1 thereby continuing the vicious cycle of glomerular injury [<xref ref-type="bibr" rid="B2">2</xref>]. In addition, angiotensin II also activates PKC and MAPK pathways, which are abundantly implicated in activation of TGF&#x003b2;1, TNF&#x003b1; and IL1, in various cells [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Over expression of TNF&#x003b1; and IL-1 stimulates the expression of chemokines like monocyte chemoattractant protein1 (MCP1) and "Regulated upon activation and normal T cell expressed and secreted" (RANTES) in human mesangial cells [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Up regulation of MCP1 and RANTES triggers recruitment of monocytes and macrophage infiltration in glomerulus of diabetic rats [<xref ref-type="bibr" rid="B15">15</xref>] and DN subjects [<xref ref-type="bibr" rid="B16">16</xref>]. Chemokine receptors, CCR2 and CCR5, are the major receptors for MCP1 and RANTES respectively and are expressed on the surface of monocytes. Wada et al [<xref ref-type="bibr" rid="B17">17</xref>] have reported that CCR5 positive cells were detected in both the glomeruli and the interstitium of human crescentic glomerulonephritis (GN) and therefore, it is speculated that CCR2 and CCR5 might be involved in the recruitment of macrophages in human DN. CCR2 and CCR5 mediated monocyte recruitment and differentiation to macrophage in the glomerulus and interstitium has been speculated to play a role in development of glomerulosclerosis and fibrosis in progressive diabetic kidney disease [<xref ref-type="bibr" rid="B18">18</xref>]. Considering such importance of inflammatory genes in development and progression of diabetic renal disease, we tested association of nine SNPs from TGF&#x003b2;1, TNF&#x003b1;, CCR2, and CCR5 genes with diabetic chronic renal insufficiency (CRI) using a case-control design.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>Ethical committee clearance for the study was obtained from the participating medical institutions and universities. In this case-control study, consecutive subjects suffering from type-2 diabetes with CRI (cases, CRI, n = 196) and diabetics without any evidence of diabetic kidney disease (controls, DM, n = 225) were recruited (after obtaining written informed consent from the study subjects) from the outpatient departments of the four participating medical institutions situated across the country. These included MS Ramiah Medical College (Bangalore), All India Institute of Medical Sciences (New Delhi), Jaipur Diabetes and Research Centre (Jaipur), and Monilek Hospital and Research Centre (Jaipur). The research carried out on study subjects was in compliance with the Helsinki Declaration [<xref ref-type="bibr" rid="B19">19</xref>]. Diabetes was diagnosed on the basis of World Health Organization guidelines. Demographic details and clinical profile of the study population have been described earlier ([<xref ref-type="bibr" rid="B3">3</xref>]; See additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). In brief, inclusion criteria for the CRI group (cases) were subjects with type-2 diabetes of &#x02265; 2 years, serum creatinine &#x02265; 3 mg/dl, urinary albumin excretion rate (AER) &#x0003e; 200 mg/l and presence of diabetic retinopathy. Patients with drug induced nephrotoxic damage or secondary causes of albuminuria such as obstructive renal disease, renal stone disease and acute urinary tract infection were excluded. Normoalbuminuric (AER&#x0003c;20 mg/l) individuals with type-2 diabetes of &#x02265; 10 years duration (average 17.07 &#x000b1; 6.69 years) were recruited as control subjects.</p></sec><sec><title>Genetic analysis</title><p>DNA from venous blood was isolated using phenol-chloroform method and used for genetic analysis. A total of nine SNPs namely -800 G&#x0003e;A, -509 C&#x0003e;T, Arg25Pro, Tyr81His and Thr263Ile in TGF&#x003b2;1gene, G&#x0003e;A (-308) in TNF&#x003b1;, Val64Ile in CCR2 gene, and CCR5&#x00394;32 and 59029 G&#x0003e;A in <italic>CCR5 </italic>gene, were genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach. Primers for all the SNPs were designed using Primer 3 software. Details including location of SNPs in the respective genes, primer sequences, PCR conditions and restriction enzyme with product sizes are presented in Table <xref ref-type="table" rid="T1">1</xref>. The digested PCR products were resolved on 2&#x02013;3% agarose gels stained with ethidium bromide.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>SNPs in TGF&#x003b2;1, TNF&#x003b1;, CCR2 and CCR5 genes, their location, primer sequences, PCR conditions and restriction enzyme with product sizes.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Polymorphism</bold></td><td align="left"><bold>Primer sequence</bold></td><td align="left"><bold>Product size (bp)</bold></td><td align="left"><bold>Annealing temp./restriction enzyme/allele sizes</bold></td></tr></thead><tbody><tr><td align="left"><bold>TGF&#x003b2;1</bold><break/><bold>G&#x0003e;A (-800)</bold><break/><bold>Promoter</bold></td><td align="left">F: 5' GGCAGTTGGCGAGAACAGT-3'<break/>R: 5' ACCCAGAACGGAAGGAGAGT3'</td><td align="left">600</td><td align="left">57&#x000b0;C/Tai I/<break/>G = 199, 401<break/>A = 600</td></tr><tr><td align="left"><bold>TGF&#x003b2;1</bold><break/><bold>C&#x0003e;T (-509)</bold><break/><bold>Promoter</bold></td><td align="left">F: 5'-GGCAGTTGGCGAGAACAGT-3'<break/>R: 5'-ACCCAGAACGGAAGGAGAGT-3'</td><td align="left">600</td><td align="left">57&#x000b0;C/Eco 8I1/<break/>C = 489,111<break/>T = 600</td></tr><tr><td align="left"><bold>TGF&#x003b2;1</bold><break/><bold>Arg25Pro</bold><break/><bold>Exon 1</bold></td><td align="left">F: 5'TTC CCT CGA GGC CCT CCT A3'<break/>R: 5' CAC AGC AGC GGT AGC AGC TG3'</td><td align="left">294</td><td align="left">61&#x000b0;C/Sac II/<break/>G = 202,67,25<break/>C = 269,25</td></tr><tr><td align="left"><bold>TGF&#x003b2;1</bold><break/><bold>Tyr81His</bold><break/><bold>Exon 2</bold></td><td align="left">F: 5' CCAGATCCTGTCCAAGCTG3'<break/>R: 5' TGGGTTTCCACCATTAGCAC3'</td><td align="left">198</td><td align="left">57&#x000b0;C/Rsa I/<break/>T = 89,109<break/>C = 198</td></tr><tr><td align="left"><bold>TGF&#x003b2;1</bold><break/><bold>Thr263Ile</bold><break/><bold>Exon 5</bold></td><td align="left">F: 5' CACCAAAGCAGGGTTCACTA3'<break/>R: 5' ATCCAGGCTACAAGGCTCA3'</td><td align="left">238</td><td align="left">58&#x000b0;C/Fok I/<break/>C = 238<break/>T = 84, 154</td></tr><tr><td align="left"><bold>TNF&#x003b1;</bold><break/><bold>G&#x0003e;A -308</bold><break/><bold>Promoter</bold></td><td align="left">F:5'AGGCAATAGGTTTTGAGGGcCAT3'<break/>R:5'GGGACACACAAGCATCAAGGATAC3'</td><td align="left">146</td><td align="left">37&#x000b0;C/Nco I/<break/>G = 146<break/>A = 122, 24</td></tr><tr><td align="left"><bold>CCR2</bold><break/><bold>Val64Ile</bold><break/><bold>Exon 1</bold></td><td align="left">F: 5'TTG TGG GCA ACA TGA TGG3'<break/>R: 5'GCA TTC CCA AAG ACC CAC TC3'</td><td align="left">163</td><td align="left">57&#x000b0;C/BsaBI/<break/>T = 163<break/>C = 145,18</td></tr><tr><td align="left"><bold>CCR5</bold><break/><bold>G&#x0003e;A (59029)</bold><break/><bold>Promoter</bold></td><td align="left">F: 5' CAG TCA ACC TGG GCA AAG CC3'<break/>R: 5' AGC TTT GGT CCT GAG AGT CC3'</td><td align="left">453</td><td align="left">57&#x000b0;C/Bst 1286I/<break/>G = 408, 45<break/>A = 453</td></tr><tr><td align="left"><bold>CCR5</bold><break/><bold>&#x00394;32</bold><break/><bold>Promoter</bold></td><td align="left">F:5' GAAGTTCCTCATTACACCTGCAGCTCTC3'<break/>R:5' CTTCTTCTCATTTCGACACCGAAGCAG AG3'</td><td align="left">174/142</td><td align="left">55&#x000b0;C/<break/>1 = 174<break/>2 = 142</td></tr></tbody></table></table-wrap></sec><sec><title>Statistical analysis</title><p>Difference in continuous and nominal clinical variables among DM (controls) and diabetic CRI (cases) groups was compared using t-test and &#x003c7;<sup>2 </sup>tests respectively. Hardy Weinberg equilibrium (HWE) was tested for each SNP using the data obtained by genotyping about 200 healthy, non-diabetic individuals from different states of India [unpublished data]. Pair wise linkage disequilibrium between multiple SNPs of a gene was calculated using EMLD Software [<xref ref-type="bibr" rid="B20">20</xref>]. Allelic and genotypic associations at each of the SNPs were tested using Pearson's &#x003c7;<sup>2 </sup>test and calculation of odds ratio (OR). Power of sample size was calculated using PAWE software [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Pair wise interactions between SNPs were assessed using logistic regression analysis. Cumulative effect of different clinical variables and SNPs was also tested by logistic and linear regression analyses using SPSS. P values &#x0003c; 0.05 were considered significant.</p></sec></sec><sec><title>Results</title><p>Clinical details of the subjects included in the study are reported and discussed somewhere else ([<xref ref-type="bibr" rid="B3">3</xref>]; See additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). In brief, No significant difference was observed in body-mass index, total serum cholesterol and triglyceride levels between the DM and CRI groups (p &#x0003e; 0.05). However, serum creatinine and blood pressure and proportion of hypertensive individuals and those with diabetic retinopathy were significantly greater (p &#x0003c; 0.05) among diabetic CRI subjects compared to DM controls.</p><sec><title>Genetic analysis</title><sec><title>TGF&#x003b2;1</title><p>Of the five SNPs selected for genotyping in this gene, two SNPs namely, Tyr81His and Thr263Ile were monomorphic and Arg25Pro was a minor variant (allele frequency of variant allele= 0.01) and therefore not analysed further. Since the r<sup>2 </sup>value between G&#x0003e;A -800 and C&#x0003e;T -509 SNPs (D' = 0.99, r<sup>2 </sup>= 0.05) was not significant both of these were genotyped in the case-control population. Neither of these two SNPs showed ether allelic or genotypic association (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Allele and genotype frequencies (F) of SNPs and their association status with chronic renal insufficiency</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>SNPs</bold></td><td align="center" colspan="2"><bold>Allele frequency</bold></td><td align="center" colspan="2"><bold>Genotype frequency</bold></td><td align="center" colspan="2"><bold>Association</bold></td></tr><tr><td></td><td align="center"><bold>DM</bold><break/><bold>F (* n)</bold></td><td align="center"><bold>CRI</bold><break/><bold>F (* n)</bold></td><td align="center"><bold>DM</bold><break/><bold>F (** n)</bold></td><td align="center"><bold>CRI</bold><break/><bold>F (** n)</bold></td><td align="center"><bold>Allele</bold><break/><bold>(df = 1)</bold></td><td align="center"><bold>Genotype</bold><break/><bold>(df = 2)</bold></td></tr></thead><tbody><tr><td align="left">TGF&#x003b2;1<break/>G&#x0003e;A (-800)</td><td align="left">G = 0.93 (418)<break/>A = 0.07 (32)</td><td align="left">G = 0.91 (356)<break/>A = 0.09 (72)</td><td align="left">GG = 0.87 (196)<break/>GA = 0.12 (27)<break/>AA = 0.01 (3)</td><td align="left">GG = 0.84(165)<break/>GA = 0.15 (29)<break/>AA = 0.01 (2)</td><td align="left">&#x003c7;<sup>2 </sup>= 0.60;<break/>P = 0.44</td><td align="left">&#x003c7;<sup>2 </sup>= 1.16;<break/>P = 0.56</td></tr><tr><td align="left">TGF&#x003b2;1<break/>C&#x0003e;T (-509)</td><td align="left">C = 0.875 (388)<break/>T = 0.125 (112)</td><td align="left">C = 0.84 (330)<break/>T = 0.16 (124)</td><td align="left">CC = 0.77 (171)<break/>CT = 0.21 (47)<break/>TT = 0.02 (4)</td><td align="left">CC = 0.72 (141)<break/>CT = 0.24 (47)<break/>TT = 0.04 (8)</td><td align="left">&#x003c7;<sup>2 </sup>= 1.24;<break/>P = 0.27</td><td align="left">&#x003c7;<sup>2 </sup>= 1.23;<break/>P = 0.54</td></tr><tr><td align="left">TNF&#x003b1;<break/>G&#x0003e;A (-308)<break/>Promoter</td><td align="left">G = 0.93 (416)<break/>A = 0.07 (32)</td><td align="left">G = 0.96 (376)<break/>A = 0.04 (16)</td><td align="left">GG = 0.87 (195)<break/>GA = 0.12 (27)<break/>AA = 0.01 (2)</td><td align="left">GG = 0.91 (178)<break/>GA = 0.08 (16)<break/>AA = 0.01 (2)</td><td align="left">&#x003c7;<sup>2 </sup>= 2.31;<break/>P = 0.13</td><td align="left">&#x003c7;<sup>2 </sup>= 2.43;<break/>P = 0.12</td></tr><tr><td align="left">CCR2<break/>C&#x0003e;T<break/>Val64Ile</td><td align="left">C = 0.91 (410)<break/>T = 0.09 (40)</td><td align="left">C = 0.94 (368)<break/>T = 0.06 (24)</td><td align="left">CC = 0.84 (189)<break/>CT = 0.15 (34)<break/>TT = 0.01 (2)</td><td align="left">CC = 0.90 (176)<break/>CT = 0.09 (18)<break/>TT = 0.01 (2)</td><td align="left">&#x003c7;<sup>2 </sup>= 2.73;<break/>P = 0.10</td><td align="left">&#x003c7;<sup>2 </sup>= 2.87;<break/>P = 0.24</td></tr><tr><td align="left">CCR<break/>5G&#x0003e;A (59029)</td><td align="left">G = 0.46 (208)<break/>A = 0.54 (242)</td><td align="left">G = 0.38 (148)<break/>A = 0.62 (244)</td><td align="left">GG = 0.21 (47)<break/>GA = 0.49 (111)<break/>AA = 0.30 (67)</td><td align="left">GG = 0.14 (27)<break/>GA = 0.48 (94)<break/>AA = 0.38 (75)</td><td align="left">&#x003c7;<sup>2 </sup>= 5.13;<break/>P = 0.02</td><td align="left">&#x003c7;<sup>2 </sup>= 5.22;<break/>P = 0.07</td></tr></tbody></table><table-wrap-foot><p>* Number of respective alleles, and ** genotypes in the study population.</p></table-wrap-foot></table-wrap></sec><sec><title>TNF&#x003b1;</title><p>No allelic or genotypic association of G&#x0003e;A (-308) promoter SNP of the gene with CRI was observed in this study (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>CCR2</title><p>No allelic or genotypic association of Val64Ile with CRI was observed in this study (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>CCR5</title><p>A significant association of allele 'A' of 59029 G&#x0003e;A SNP with CRI was observed (OR 1.39, CI 1.04&#x02013;1.84, p = 0.02). CCR5&#x00394;32 polymorphism was only a minor variant and therefore, not included for case-control association.</p><p>In a univariate logistic regression analysis, keeping disease status (DM or CRI) as dependent variable and all the genotypes as independent variables, we observed a significant association of the genotype GA (OR 1.95, CI 1.07&#x02013;3.55, p = 0.028) of 59029 G&#x0003e;A SNP with CRI. In a multiple logistic regression analysis keeping disease status (DM or CRI) as dependent variable and all the genotypes and crucial clinical parameters as independent variables no association of any of the polymorphisms or clinical parameters with CRI was observed. Pair wise interactions tested between different SNPs using logistic regression were not found to be significantly associated with diabetic kidney disease.</p><p>An additional, sub-analysis of diabetic CRI category using retinopathy status (proliferative vs. non-proliferative) as dependent variable and genotypes (all the polymorphisms analysed in this study) as independent variables was performed using univariate logistic regression (Table <xref ref-type="table" rid="T3">3</xref>). A compound group of genotypes 'GA and AA' of SNP G&#x0003e;A -800 was found to confer predisposition in only those diabetic CRI patients with proliferative retinopathy (OR 3.03, CI 1.08&#x02013;8.50, p = 0.035).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>A sub-analysis of case (CRI) category using proliferative retinopathy as an outcome variable</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>SNP</bold></td><td align="left"><bold>P</bold></td><td align="left"><bold>Exp(B)</bold></td><td align="center" colspan="2"><bold>95% C.I. for Exp(B)</bold></td></tr><tr><td></td><td></td><td></td><td align="left"><bold>Lower</bold></td><td align="left"><bold>Upper</bold></td></tr></thead><tbody><tr><td align="left">TGF &#x003b2;1<break/>G&#x0003e;A (-800)</td><td align="left">0.031</td><td align="left">0.336</td><td align="left">0.124</td><td align="left">0.908</td></tr><tr><td align="left">TGF &#x003b2;1<break/>C&#x0003e;T (-509)</td><td align="left">0.21</td><td align="left">0.743</td><td align="left">0.466</td><td align="left">1.183</td></tr><tr><td align="left">CCR2<break/>C&#x0003e;T<break/>Val64Ile</td><td align="left">0.797</td><td align="left">0.879</td><td align="left">0.330</td><td align="left">2.345</td></tr><tr><td align="left">TNF &#x003b1;<break/>G&#x0003e;A (-308)</td><td align="left">0.58</td><td align="left">0.70</td><td align="left">0.20</td><td align="left">2.48</td></tr><tr><td align="left">CCR5<break/>G&#x0003e;A (-59029)</td><td align="left">0.988</td><td align="left">1.044</td><td align="left">0.627</td><td align="left">1.606</td></tr></tbody></table></table-wrap></sec></sec></sec><sec><title>Discussion</title><p>Chronic renal insufficiency due to diabetes is the most frequent cause of death due to end stage renal disease and thus a major health concern world over [<xref ref-type="bibr" rid="B23">23</xref>]. Contemporary evidences both from <italic>in vitro </italic>and <italic>in vivo </italic>studies in experimental animals and renal biopsy specimens from patients with progressive diabetic renal disease suggest that cytokines play crucial role in development and progression of diabetic kidney disease [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Moreover, results from our previous report [<xref ref-type="bibr" rid="B3">3</xref>] suggested that the effect of RAAS may not be mediated through modulation of hypertension as a crucial mechanism for development of CRI but it may operate by stimulation of inflammatory genes. Therefore, in this case-control study genetic contribution of nine SNPs from TGF&#x003b2;1, TNF&#x003b1;, CCR2 and CCR5 genes for CRI among individuals with type2 diabetes have been analysed. We observed a significant allelic association of allele "A" of SNP 59029 G&#x0003e;A in chemokine receptor-5 gene with diabetic CRI.</p><p>Neither of the two promoter SNPs (G&#x0003e;A -800 and C&#x0003e;T -509) of TGF&#x003b2;1 gene showed association with CRI in this study. These SNPs have not been tested for association with diabetic nephropathy in any other population and thus no comparison is possible. However, a study reported a significant association of C&#x0003e;T-509 (p = 0.02) SNPs in TGF&#x003b2;1 gene polymorphisms with chronic kidney failure in European population [<xref ref-type="bibr" rid="B27">27</xref>]. Another study, which investigated association of two polymorphisms inTGF&#x003b2;1 gene, reported a significant association of Arg25Pro inTGF&#x003b2;1 gene with end-stage renal disease [<xref ref-type="bibr" rid="B28">28</xref>]. However, in our population since SNP Arg25Pro was found to be a minor variant (with frequency of variant allele = 0.01, unpublished data), it was non-informative. Lack of association of CCR2 Val64Ile SNP in our study is similar to other reports from Japanese population [<xref ref-type="bibr" rid="B14">14</xref>]. As for association of CCR5 gene polymorphisms with CRI, we observed a strong trend of association of 59029 G&#x0003e;A SNP. This is in conformity with two other available reports of association of this marker with DN among Japanese population [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Though the allele 'A' is predominant in both control (DM) and case (CRI) groups, in our sample set, the allele frequency is significantly higher in CRI group (P = 0.02) and seems to be predisposing based on OR estimates (OR: 1.39; CI: 1.04&#x02013;1.84). An enhanced expression of CCR5 by peripheral blood mononuclear cells has been seen in individuals with the CCR5 59029A-genotype [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>], thereby suggesting that the genotype could regulate CCR5 gene expression. This further corroborates our observation of association of allele 'A' with the disease. Considering the important role of CCR5 gene in macrophage infiltration into glomerulus and interstitium, our observation of association of promoter SNP in seems exciting but in view of the sub-optimal power of the sample analysed (G = 29%), a replication study seems warranted.</p><p>Following analysis on the two sub groups of CRI patients, one with and the other without proliferative retinopathy (PR), a compound group of genotypes 'GA and AA' of SNP G&#x0003e;A -800 in TGF&#x003b2;1 gene was found to confer predisposition (P = 0.035; OR: 3.028; CI: 1.079&#x02013;8.50) only in those CRI patients with proliferative retinopathy (Table <xref ref-type="table" rid="T3">3</xref>). TGF&#x003b2;1 gene has been known to influence almost every pathway implicated in development of diabetic CRI [<xref ref-type="bibr" rid="B32">32</xref>]. Therefore, considering that TGF&#x003b2;1 plays a very crucial role in diabetic CRI progression and development, our finding seems promising. However, due to relatively small sample size after sub-grouping in this analysis, we would be cautious in interpreting our results.</p></sec><sec><title>Conclusion</title><p>In conclusion, our results suggest that 59029 G&#x0003e;A SNP in CCR5 gene may play a role in CRI susceptibility in the Asian Indian population.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>All authors have read and approved the final Ms. PP was involved in the study design, carried out molecular genetics and statistical analyses, compiled the data, wrote the Ms.; AKT was involved in molecular genetic analysis; KMPK, ACA, AG, and RG were the principal clinical investigators involved in study design, defining exclusion and inclusion criteria of study subjects and were mainly responsible for identification of study subjects from their respective clinical centres; BKT was the principal geneticist and coordinator of the project, involved in conceptualization of the project, study design, oversee complete genetic analyses in the laboratory, critical inputs and finalization of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/20/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional File 1</title><p>Clinical characteristics of the study population. The data provided represent the demographic and clinical characteristics of the study population.</p></caption><media xlink:href="1471-2350-8-20-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>BJ</given-names></name><name><surname>van Haeften</surname><given-names>TW</given-names></name></person-group><article-title>Type 2 diabtes: principls of pathogenesis and therapy</article-title><source>Lancet</source><year>2005</year><fpage>1333</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">15823385</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)61032-X</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>CA</given-names></name><name><surname>Raij</surname><given-names>L</given-names></name></person-group><article-title>Interaction of hemodynamic and metabolic pathways in the genesis of diabetic nephropathy</article-title><source>J Hypertens</source><year>2005</year><volume>23</volume><fpage>1931</fpage><lpage>1937</lpage><pub-id pub-id-type="pmid">16208129</pub-id><pub-id pub-id-type="doi">10.1097/01.hjh.0000188415.65040.5d</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>P</given-names></name><name><surname>Tiwari</surname><given-names>AK</given-names></name><name><surname>Kumar</surname><given-names>KM</given-names></name><name><surname>Ammini</surname><given-names>AC</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>AK</given-names></name><name><surname>Rao</surname><given-names>AR</given-names></name><name><surname>Nagendra</surname><given-names>R</given-names></name><name><surname>Chandra</surname><given-names>TS</given-names></name><name><surname>Tiwari</surname><given-names>SC</given-names></name><name><surname>Rastogi</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>BL</given-names></name><name><surname>Thelma</surname><given-names>BK</given-names></name></person-group><article-title>Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms</article-title><source>BMC Med Gen</source><year>2006</year><volume>7</volume><fpage>e42</fpage><pub-id pub-id-type="doi">10.1186/1471-2350-7-42</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keven</surname><given-names>K</given-names></name><name><surname>Ekmecki</surname><given-names>Y</given-names></name></person-group><article-title>Opposing mechanisms in tubulogomrular feedback</article-title><source>Am J Kid Dis</source><year>2004</year><volume>44</volume><fpage>574</fpage><pub-id pub-id-type="pmid">15332234</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raij</surname><given-names>L</given-names></name><name><surname>Azar</surname><given-names>S</given-names></name><name><surname>Keane</surname><given-names>WF</given-names></name></person-group><article-title>Role of hypertension in progressive glomerular immune injury</article-title><source>Hypertens</source><year>1985</year><volume>3</volume><fpage>398</fpage><lpage>404</lpage></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gnudi</surname><given-names>L</given-names></name><name><surname>Viberti</surname><given-names>G</given-names></name><name><surname>Raij</surname><given-names>L</given-names></name><name><surname>Rodriguez</surname><given-names>V</given-names></name><name><surname>Burt</surname><given-names>D</given-names></name><name><surname>Cortes</surname><given-names>P</given-names></name><name><surname>Hartley</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Maestrini</surname><given-names>S</given-names></name><name><surname>Gruden</surname><given-names>G</given-names></name></person-group><article-title>GLUT-1 overexpression: Link between hemodynamic and metabolic factors in glomerular injury?</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12771048</pub-id><pub-id pub-id-type="doi">10.1161/01.HYP.0000075949.19968.EF</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>G</given-names></name></person-group><article-title>New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology</article-title><source>Eur J Clin Invest</source><year>2004</year><volume>34</volume><fpage>785</fpage><lpage>96</lpage><comment>Review</comment><pub-id pub-id-type="pmid">15606719</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2362.2004.01429.x</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weigert</surname><given-names>C</given-names></name><name><surname>Brodbeck</surname><given-names>K</given-names></name><name><surname>Klopfer</surname><given-names>K</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><name><surname>Schleicher</surname><given-names>ED</given-names></name></person-group><article-title>Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia</article-title><source>Diabetologia</source><year>2002</year><volume>45</volume><fpage>890</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12107734</pub-id><pub-id pub-id-type="doi">10.1007/s00125-002-0843-4</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fumo</surname><given-names>P</given-names></name><name><surname>Kuncio</surname><given-names>GS</given-names></name><name><surname>Ziyadeh</surname><given-names>FN</given-names></name></person-group><article-title>PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line</article-title><source>Am J Physiol</source><year>1994</year><volume>267</volume><fpage>F632</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7524361</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Jirousek</surname><given-names>MR</given-names></name><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Kuboki</surname><given-names>K</given-names></name><name><surname>King</surname><given-names>GL</given-names></name></person-group><article-title>Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats</article-title><source>J Clin Invest</source><volume>100</volume><fpage>115</fpage><lpage>26</lpage><comment>1997 Jul 1</comment><pub-id pub-id-type="pmid">9202063</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nomiyama</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>F</given-names></name><name><surname>Kanno</surname><given-names>R</given-names></name><name><surname>Iwashita</surname><given-names>N</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Watada</surname><given-names>H</given-names></name><name><surname>Onuma</surname><given-names>T</given-names></name><name><surname>Kawamori</surname><given-names>R</given-names></name></person-group><article-title>RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>892</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12610055</pub-id><pub-id pub-id-type="doi">10.2337/diacare.26.3.892</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>G</given-names></name><name><surname>Aberle</surname><given-names>S</given-names></name><name><surname>Thaiss</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>PJ</given-names></name><name><surname>Krensky</surname><given-names>AM</given-names></name><name><surname>Neilson</surname><given-names>EG</given-names></name><name><surname>Stahl</surname><given-names>RA</given-names></name></person-group><article-title>TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells</article-title><source>Kidney Int</source><year>1993</year><volume>44</volume><fpage>795</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">7505037</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>M</given-names></name><name><surname>Radeke</surname><given-names>HH</given-names></name><name><surname>Resch</surname><given-names>K</given-names></name><name><surname>Uciechowski</surname><given-names>P</given-names></name></person-group><article-title>Lymphocyte-derived cytokines induce sequential expression of monocyte- and T cell-specific chemokines in human mesangial cells</article-title><source>Kidney Int</source><year>1997</year><volume>52</volume><fpage>1521</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">9407497</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nomiyama</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Piao</surname><given-names>L</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Onuma</surname><given-names>T</given-names></name><name><surname>Kawamori</surname><given-names>R</given-names></name></person-group><article-title>Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>238</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11756347</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.51.1.238</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sassy-Prigent</surname><given-names>C</given-names></name><name><surname>Heudes</surname><given-names>D</given-names></name><name><surname>Mandet</surname><given-names>C</given-names></name><name><surname>Belair</surname><given-names>MF</given-names></name><name><surname>Michel</surname><given-names>O</given-names></name><name><surname>Perdereau</surname><given-names>B</given-names></name><name><surname>Bariety</surname><given-names>J</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name></person-group><article-title>Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>466</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">10868970</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.49.3.466</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Ootaka</surname><given-names>T</given-names></name><name><surname>Soma</surname><given-names>J</given-names></name><name><surname>Obara</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Yoshinaga</surname><given-names>K</given-names></name></person-group><article-title>The role of macrophages in diabetic glomerulosclerosis</article-title><source>Am J Kidney Dis</source><year>1993</year><volume>21</volume><fpage>480</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8488815</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name></person-group><article-title>Chemokines new target molecules in renal diseases</article-title><source>Clin Exp Nephrol</source><year>2000</year><volume>4</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1007/s101570070001</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlondorff</surname><given-names>D</given-names></name><name><surname>Nelson</surname><given-names>PJ</given-names></name><name><surname>Luckow</surname><given-names>B</given-names></name><name><surname>Banas</surname><given-names>B</given-names></name></person-group><article-title>Chemokines and renal disease</article-title><source>Kidney Int</source><year>1997</year><volume>51</volume><fpage>610</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9067891</pub-id></citation></ref><ref id="B19"><citation citation-type="other"><ext-link ext-link-type="uri" xlink:href="http://www.wma.net/e/policy/b3.htm"/></citation></ref><ref id="B20"><citation citation-type="other"><ext-link ext-link-type="uri" xlink:href="http://linkage.rockefeller.edu/soft/"/></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Finch</surname><given-names>SJ</given-names></name><name><surname>Nothnagel</surname><given-names>M</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name></person-group><article-title>Power and sample size calculations for case-control genetic association tests when errors present: application to single nucleotide polymorphisms</article-title><source>Human Heredity</source><year>2002</year><volume>54</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12446984</pub-id><pub-id pub-id-type="doi">10.1159/000066696</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Levenstien</surname><given-names>MA</given-names></name><name><surname>Finch</surname><given-names>SJ</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name></person-group><article-title>Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies</article-title><source>Pacific Symposium on Biocomputing</source><year>2003</year><fpage>490</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">12603052</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rincon-Choles</surname><given-names>H</given-names></name><name><surname>Thameem</surname><given-names>F</given-names></name><name><surname>Lehman</surname><given-names>DM</given-names></name><name><surname>Arya</surname><given-names>R</given-names></name><name><surname>Arar</surname><given-names>N</given-names></name><name><surname>Duggirala</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>MP</given-names></name><name><surname>Abboud</surname><given-names>HE</given-names></name></person-group><article-title>Genetic basis of diabetic nephropathy</article-title><source>Am J Ther</source><year>2005</year><volume>12</volume><fpage>555</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">16280649</pub-id><pub-id pub-id-type="doi">10.1097/01.mjt.0000178770.52610.bf</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Noble</surname><given-names>NA</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name><name><surname>Border</surname><given-names>WA</given-names></name></person-group><article-title>Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>1814</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7680480</pub-id><pub-id pub-id-type="doi">10.1073/pnas.90.5.1814</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwano</surname><given-names>M</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Nishino</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Nishioka</surname><given-names>H</given-names></name><name><surname>Akai</surname><given-names>Y</given-names></name><name><surname>Kurioka</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Kanauchi</surname><given-names>M</given-names></name><name><surname>Shiiki</surname><given-names>H</given-names></name><name><surname>Dohi</surname><given-names>K</given-names></name></person-group><article-title>Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus</article-title><source>Kidney Int</source><year>1996</year><volume>49</volume><fpage>1120</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8691733</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Border</surname><given-names>WA</given-names></name><name><surname>Noble</surname><given-names>NA</given-names></name></person-group><article-title>Transforming growth factor beta in tissue fibrosis</article-title><source>N Engl J Med</source><volume>331</volume><fpage>1286</fpage><lpage>92</lpage><comment>1994 Nov 10; Lab Invest 68: 154&#x02013;163, 1993</comment><pub-id pub-id-type="pmid">7935686</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199411103311907</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>MS</given-names></name><name><surname>El Nahas</surname><given-names>AM</given-names></name><name><surname>Blakemore</surname><given-names>AI</given-names></name></person-group><article-title>Transforming growth factor-beta1 SNPs: genetic and phenotypic correlations in progressivekidney insufficiency</article-title><source>Nephron Exp Nephrol</source><year>2005</year><volume>101</volume><fpage>e31</fpage><lpage>41</lpage><comment>Epub 2005 Jun 7</comment><pub-id pub-id-type="pmid">15942255</pub-id><pub-id pub-id-type="doi">10.1159/000086227</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coll</surname><given-names>E</given-names></name><name><surname>Cormand</surname><given-names>B</given-names></name><name><surname>Campos</surname><given-names>B</given-names></name><name><surname>Gonzalez-Nunez</surname><given-names>D</given-names></name><name><surname>Inigo</surname><given-names>P</given-names></name><name><surname>Botey</surname><given-names>A</given-names></name><name><surname>Poch</surname><given-names>E</given-names></name></person-group><article-title>Association of TGF-beta1 polymorphisms with chronic renal disease</article-title><source>J Nephrol</source><year>2004</year><volume>17</volume><fpage>794</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15593053</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mokubo</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Watada</surname><given-names>H</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><name><surname>Kawasumi</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Kanazawa</surname><given-names>A</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Hosokawa</surname><given-names>K</given-names></name><name><surname>Atsumi</surname><given-names>Y</given-names></name><name><surname>Matsuoka</surname><given-names>K</given-names></name><name><surname>Kawamori</surname><given-names>R</given-names></name></person-group><article-title>Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study</article-title><source>Diabetes Res Clin Pract</source><year>2006</year><volume>73</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16442182</pub-id><pub-id pub-id-type="doi">10.1016/j.diabres.2005.12.006</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>DH</given-names></name><name><surname>Zimmerman</surname><given-names>PA</given-names></name><name><surname>Guignard</surname><given-names>F</given-names></name><name><surname>Kleeberger</surname><given-names>CA</given-names></name><name><surname>Leitman</surname><given-names>SF</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><article-title>CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS)</article-title><source>Lancet</source><volume>352</volume><fpage>866</fpage><lpage>70</lpage><comment>1998 Sep 12</comment><pub-id pub-id-type="pmid">9742978</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)04158-0</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shieh</surname><given-names>B</given-names></name><name><surname>Liau</surname><given-names>YE</given-names></name><name><surname>Hsieh</surname><given-names>PS</given-names></name><name><surname>Yan</surname><given-names>YP</given-names></name><name><surname>Wang</surname><given-names>ST</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4</article-title><source>Int Immunol</source><year>2000</year><volume>12</volume><fpage>1311</fpage><lpage>1318</lpage><pub-id pub-id-type="pmid">10967026</pub-id><pub-id pub-id-type="doi">10.1093/intimm/12.9.1311</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziyadeh</surname><given-names>FN</given-names></name></person-group><article-title>Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><fpage>S55</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14684674</pub-id><pub-id pub-id-type="doi">10.1097/01.ASN.0000093460.24823.5B</pub-id></citation></ref></ref-list></back></article> 